Augmedics announced today that it launched new, FDA-cleared features and indications for its Xvision Spine System.
Updates to Xvision come just weeks after the company hit its 3,000-patient milestone for the system. It marks Xvision’s largest expansion since its commercial launch.
Chicago-based Augmedics said in a news release that the launch creates a technical foundation for future platform developments, too.
Augmedics added new features including artificial intelligence (AI)-based image enhancement functionalities. Xvision now also features new customizable views to expand its advanced visualization and customization capabilities.
The system now includes new cervical and iliosacral indications, joining existing thoracic, lumbar and sacral indications. This expands Xvision navigation to cover nearly the entire spine. Surgeons can now utilize the advantages of its navigation in posterior cervical and pelvic approaches, Augmedics said.
Augmedics began a rollout for the new updates to its user base across 21 U.S. states in early January. The company estimates completion of its rollout by the end of the first quarter. It said feedback so far has been “overwhelmingly positive.”
“This is a significant step forward for xvision in what is proving already to be a noteworthy year,” said Augmedics President & CEO Kevin Hykes. “Our new cervical and iliosacral indications mean more surgeons – and consequently more patients – are benefiting from the accuracy, precision, and confidence of xvision navigation. We are also thrilled to launch our first application of AI, which represents the tip of the iceberg in terms of decision support and planning tools for surgeons. These new capabilities and indications are an exciting step into the future as we continue to revolutionize the field of augmented reality navigation.”